(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

9 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    Int J Stem Cells, 2018, 11(1):131-140. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

    immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M2fxb2NmdGxiVnnhZoltcXS7IFHzd4F6 NVfHOol7OjVyL{WwNE8yODByIH7N MmrxNlQwPDhxN{KgbC=> MV7EUXNQ MXLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NXy4[3d3OjZ5MEe4PFE>
BCPAP MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NILjcGQzPTBxNUCwM|ExODBibl2= NGTifYkzPC92OD:3NkBp MWnEUXNQ MljvbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MlvuNlY4ODd6OEG=
K1  NFew[GJE\WyuIFP5Z4xmKEG|c3H5 M33rNVI2OC93MECvNVAxOCCwTR?= M1fQVVczKGh? NXzSTVBUTE2VTx?= MorJZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NXjiWIxGOjZ5MEe4PFE>
BCPAP MnvUR4VtdCCFeXPs[UBCe3OjeR?= M{PQTFI2OC93MECvNVAxOCCwTR?= M1\SeVczKGh? NWOxZpRVTE2VTx?= MlrOZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NI\kOVAzPjdyN{i4NS=>
Hep3B MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT4ephkOC1zMDFOwG0> MYS1JIQ> MlTtSG1UVw>? NUXQR4FmUUN3ME2wMlA5KM7:TR?= MXeyOlU4PTF4Nx?=
HCCLM3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nJdFAuOTBizszN M3j0S|Uh\A>? MUjEUXNQ MVHJR|UxRTBwMUSg{txO M13ZSVI3PTd3MU[3
HuH7 M{XSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMVExKM7:TR?= NV;ETll2PSCm M1rHN2ROW09? M4LwXmlEPTB;MD6yNUDPxE1? MXyyOlU4PTF4Nx?=
HepG2 M1r6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\vNE0yOCEQvF2= M2Pwd|Uh\A>? NXj3XWJ2TE2VTx?= MULJR|UxRTBwM{Sg{txO MXqyOlU4PTF4Nx?=
SMMC7721 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDWbJY{OC1zMDFOwG0> MnfyOUBl MWXEUXNQ NWr6XW5DUUN3ME2wMlQyKM7:TR?= NUjMW3ZuOjZ3N{WxOlc>
BEL7402 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[wMVExKM7:TR?= NWnESpo5PSCm MWjEUXNQ M4LuW2lEPTB;MD60O{DPxE1? Mnn2NlY2PzVzNke=
MHCC97H M4WyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHYOVZuOC1zMDFOwG0> NHXkdWE2KGR? M{TmXmROW09? NF\UcW1KSzVyPUCuOFEh|ryP MWmyOlU4PTF4Nx?=
Hep3B NVHH[2h[S2WubDDDfYNt\SCDc4PhfS=> NVHFNFljOC5zL{CuOU8zNjVizszN MYC0PEBp NWW4SmQ4TE2VTx?= MVzs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> NHXiPGQzPjV5NUG2Oy=>
HCCLM3 MUXD[YxtKEO7Y3zlJGF{e2G7 NFfNW2gxNjFxMD61M|IvPSEQvF2= M{PpZlQ5KGh? NVHX[lkxTE2VTx?= MnrucIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh NEn3UYwzPjV5NUG2Oy=>
Hep3B Mn7KRZBweHSxc3nzJGF{e2G7 MUmwMlEwOC53L{KuOUDPxE1? M1XEd|Q5KGh? MkP2SG1UVw>? MkDrZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? NV34emIyOjZ3N{WxOlc>
HCCLM3 M1LYTmFxd3C2b4Ppd{BCe3OjeR?= MV6wMlEwOC53L{KuOUDPxE1? Mm\qOFghcA>? NFzkcmhFVVOR M2\0cYFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? MXSyOlU4PTF4Nx?=
A549 MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;EbpcxNjFvMUCg{txO NUHlXIpiPzJiaB?= M3nkOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoHLNlY1OTV{MkW=
H157 M4OzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmwMlEuOTBizszN NEDSZYQ4OiCq MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3TS[FI3PDF3MkK1
H1299 NFPzU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrSfIgxNjFvMUCg{txO NWXEXlBjPzJiaB?= MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVmyOlQyPTJ{NR?=
A549 MmKxSpVv[3Srb36gRZN{[Xl? NXjMVo5ZOS9{LkWvOUDPxE1? MUGxNkBp MVtCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ M3TyclI3PDF3MkK1
H1299 Mkf1SpVv[3Srb36gRZN{[Xl? NVfDVpNyOS9{LkWvOUDPxE1? NIPG[HgyOiCq NVvCOGw2yqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= NXPPRYpZOjZ2MUWyNlU>
H157 MmPrSpVv[3Srb36gRZN{[Xl? MV[xM|IvPS93IN88US=> M{PLclEzKGh? NEnRO|Bl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= NV;qXphrOjZ2MUWyNlU>
H1299 NFHxS2tHfW6ldHnvckBCe3OjeR?= Ml\JNU8zNjVxNTFOwG0> NH3rclIyOiCq Mn7G[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w MWiyOlQyPTJ{NR?=
C8161 M1XMXmNmdGxiVnnhZoltcXS7IFHzd4F6 Mm\GNE0zKM7:TR?= NHW1RYw1KGR? M1zhNGROW09? Mknn[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYSzelN7OjZ|OUeyNlM>
Mel285 MnLaR4VtdCCYaXHibYxqfHliQYPzZZk> NV3jOnFXOC1{IN88US=> NIm0Rpg1KGR? MUnEUXNQ MlXu[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3jMdFI3Ozl5MkKz
Mel290 MonLR4VtdCCYaXHibYxqfHliQYPzZZk> NFfGOIIxNTJizszN NIDiT5o1KGR? M3Lt[2ROW09? MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVKyOlM6PzJ{Mx?=
92.1 NWfzNlRRS2WubDDWbYFjcWyrdImgRZN{[Xl? NHLMeIoxNTJizszN MUi0JIQ> NETQfY5FVVOR MoXO[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWGyOlM6PzJ{Mx?=
Omm1.3 M{\WcGNmdGxiVnnhZoltcXS7IFHzd4F6 MWmwMVIh|ryP MUe0JIQ> MkXkSG1UVw>? Mn3I[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYLZVWhROjZ|OUeyNlM>
Mel202 NH7sUXBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3XlSlAuOiEQvF2= MlO3OEBl NHvjV|dFVVOR NFTRVWJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUiyOlM6PzJ{Mx?=
Mel270 MmO3R4VtdCCYaXHibYxqfHliQYPzZZk> Mn7XNE0zKM7:TR?= NGjPZ4Y1KGR? NGPyPVJFVVOR MXnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVuyOlM6PzJ{Mx?=
Omm1 NH\2SJVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoXuNE0zKM7:TR?= Ml2xOEBl MYDEUXNQ NHLjOXhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYG4W3p2OjZ|OUeyNlM>
92.1 NULmTZFsSXCxcITvd4l{KEG|c3H5 NUPUdml7PTByIH7N M4n3OFQ5KGh? MXPEUXNQ MVvpcoR2[2W|IHHwc5B1d3Orcx?= M1\UZVI3Ozl5MkKz
Omm1.3 MUjBdI9xfG:|aYOgRZN{[Xl? NXPENGxmPTByIH7N NEKxdIo1QCCq M3TG[WROW09? M3ruUIlv\HWlZYOgZZBweHSxc3nz MYqyOlM6PzJ{Mx?=
92.1 M{f6bmNmdGxiQ4njcIUhSXO|YYm= NX\MfINRPTByIH7N M3jqbVI1NzR6L{eyJIg> MlLmSG1UVw>? NXrGZVZZcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= M3\GVlI3Ozl5MkKz
Omm1.3 MX;D[YxtKEO7Y3zlJGF{e2G7 M4r4N|UxOCCwTR?= Mke2NlQwPDhxN{KgbC=> Mnz4SG1UVw>? NH74S4lqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= MnjVNlY{QTd{MkO=
A549 MX3GeY5kfGmxbjDBd5NigQ>? NYLpbmRbOTByL{SwNE8yODByIH7N NEDQbpYzPCCq Ml3CeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? MmfwNlYzOTJzOUm=
MCF-7 MlKzSpVv[3Srb36gRZN{[Xl? NX61fHQ1OTByL{SwNE8yODByIH7N MYGyOEBp NWS1[mZIfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NGDWOpYzPjJzMkG5PS=>
HEK293 MoXISpVv[3Srb36gRZN{[Xl? M3HpfVExOC92MECvNVAxOCCwTR?= MWiyOEBp NWDlSGVFfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NHrpN2YzPjJzMkG5PS=>
858 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXewMVEh|ryP NWrzd|MyPSCm MlnTSG1UVw>? M4f4S4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NH\5SoUzPjJyNkOzNy=>
DDR2L63V NGnETZZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn:3NE0yKM7:TR?= NYHyVWFHPSCm NFmxbFZFVVOR MXPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH\peGozPjJyNkOzNy=>
BE(2)-C M2ftRWNmdGxiVnnhZoltcXS7IFHzd4F6 NHvW[5EyKM7:TR?= M{jmTVEuPCCm NHjrbWRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NWP0TZJvOjZyNke0OlQ>
IMR-32 NH31SpdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoPENUDPxE1? NHjMfWYyNTRiZB?= MnHk[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NUfITJRqOjZyNke0OlQ>
JF MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{XLUlEh|ryP MV:xMVQh\A>? MXHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> Mm\aNlYxPjd2NkS=
BE(2)-M17 MlmwR4VtdCCYaXHibYxqfHliQYPzZZk> MlvJNUDPxE1? NH;ZZXoyNTRiZB?= MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MknKNlYxPjd2NkS=
SK-N-SH MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2C3SlEh|ryP M{e5T|EuPCCm MnnS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M2nWZlI3ODZ5NE[0
SK-N-DZ  MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFjK[WgyKM7:TR?= NULjSFFqOS12IHS= MVnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> Ml3FNlYxPjd2NkS=
HMC-1.1  MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK2XVk2NTVyMECgcm0> Ml64OFghcA>? MVLEUXNQ M3vrTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH75[lQzPjB3NUOwNy=>
HMC-1.2 M1XVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PjcFUuPTByMDDuUS=> M1;WVFQ5KGh? Mn;qSG1UVw>? M1jLeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVeyOlA2PTNyMx?=
ROSA KIT WT  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDxOU02ODByIH7N MkHGOFghcA>? MX3EUXNQ M2rxbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYCyOlA2PTNyMx?=
ROSA KIT D816V NVjpXol5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn4OU02ODByIH7N MkfOOFghcA>? NYn1d|NPTE2VTx?= MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{LKN|I3ODV3M{Cz
HMC-1.1  MULBdI9xfG:|aYOgRZN{[Xl? NGmxRVUzODBvNUCwNEBvVQ>? MVe0PEBp NYfrNYxbTE2VTx?= MnvqbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnnuNlYxPTV|MEO=
HMC-1.2 NGriUnpCeG:ydH;zbZMhSXO|YYm= MYmyNFAuPTByMDDuUS=> MYO0PEBp NF\qTHBFVVOR MoX1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYT4V4x6OjZyNUWzNFM>
ROSA KIT WT  NYryUZRNSXCxcITvd4l{KEG|c3H5 MYSyNFAuPTByMDDuUS=> NGS4UXg1QCCq MlfuSG1UVw>? MlrobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXXLZZRUOjZyNUWzNFM>
ROSA KIT D816V Mlr2RZBweHSxc3nzJGF{e2G7 MmLKNlAxNTVyMECgcm0> MYK0PEBp NGHCO3JFVVOR M4T3colv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIC2U2UzPjB3NUOwNy=>
494H MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvKd4FUPzJiaB?= NWrkW5FmTE2VTx?= NUXPZYtsUUN3ME2wMlEzOsLzMD6wNFQh|ryP MkDrNlU6PDR3Nk[=
493H MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLJO|IhcA>? NEjMVY5FVVOR Mo\hTWM2OD1yLkC0O:KyOC5yMEmg{txO MV2yOVk1PDV4Nh?=
716H NUS5bZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLDNm44OiCq MmP5SG1UVw>? MVHJR|UxRTBwMkGyxtExNjB|NDFOwG0> NEGzV5YzPTl2NEW2Oi=>
148I M4n5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW5O|IhcA>? NULKfYxOTE2VTx?= M2XIeGlEPTB;MD6yPFTDuTBwMEO1JO69VQ>? NYG4fnE3OjV7NES1OlY>
98Sc Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp MYnEUXNQ NHXIT4NKSzVyPUCuNVE2yrFyLkCwOEDPxE1? NVP1fYJNOjV7NES1OlY>
89R MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPCVZg4OiCq MormSG1UVw>? MVrJR|UxRTBwMUK2xtExNjByMzFOwG0> M4DRWlI2QTR2NU[2
494L NGjN[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xO|IhcA>? Mk\ESG1UVw>? NH\pcnBKSzVyPUCuN|E4yrFyLkCxNkDPxE1? M1XkRVI2QTR2NU[2
493L Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qzeFczKGh? MUjEUXNQ NYP2em5{UUN3ME2wMlA2OMLzMD6wNVEh|ryP M3fLbVI2QTR2NU[2
148L MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\6ZppPPzJiaB?= NGTmZYZFVVOR NY\DclNwUUN3ME2wMlE1PsLzMD6wNVch|ryP NFzaOVczPTl2NEW2Oi=>
98L MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jtdVczKGh? M3f4[mROW09? NXjWfXJJUUN3ME2wMlMxQcLzMD6wNlkh|ryP NWD4Sot4OjV7NES1OlY>
OS17 NGLLdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz5O|IhcA>? M17ESmROW09? MnvwTWM2OD1yLkC3PeKyOC5yMEOg{txO MX6yOVk1PDV4Nh?=
OS9 NUTPZYpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG3NkBp MUnEUXNQ NFHLeo1KSzVyPUCuOFA3yrFyLkCyPEDPxE1? MkHONlU6PDR3Nk[=
MG63 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq2e5dzPzJiaB?= MXnEUXNQ NY\wWHFlUUN3ME2wMlEyPMLzMD6wNlUh|ryP NE\hWnQzPTl2NEW2Oi=>
SAOS2 M1rac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD4O|IhcA>? MWDEUXNQ NXLzcGszUUN3ME2wMlIyP8LzMD6wNFMh|ryP Mn7LNlU6PDR3Nk[=
U2OS Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ZO|IhcA>? NYjXTYE4TE2VTx?= M{iwNWlEPTB;MD6xPVjDuTBwMEC4JO69VQ>? M4HWc|I2QTR2NU[2
SJSA-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHCO|IhcA>? NWrtV3dxTE2VTx?= MoPkTWM2OD1yLkGwNOKyOC5yMUCg{txO Mm\ENlU6PDR3Nk[=
494H MlG5RZBweHSxc3nzJGF{e2G7 MnrJNE4zPS9yLkWvNU4xKM7:TR?= NHnhfnQzPCCq MkTaSG1UVw>? NGLCUphqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? M4r1elI2QTR2NU[2
148I M4THRWFxd3C2b4Ppd{BCe3OjeR?= M2TKWlAvOjVxMD61M|EvOCEQvF2= M1i2UVI1KGh? M1HNdWROW09? NGOxdm5qdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? NEH1[Y4zPTl2NEW2Oi=>
OS17 NX7lU3p5SXCxcITvd4l{KEG|c3H5 MXOwMlI2NzBwNT:xMlAh|ryP MVGyOEBp M1P0dWROW09? M170Rolv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NEXGN|AzPTl2NEW2Oi=>
494H MkP2RZBweHSxc3nzJGF{e2G7 NFLQZXQy6oDLzszN M{DTflQ5KGh? MnLWSG1UVw>? MmnMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NYHCT2FOOjV7NES1OlY>
148I M3;CSGFxd3C2b4Ppd{BCe3OjeR?= MU[x5qCK|ryP MWG0PEBp M2PmcmROW09? MnLPbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NVjKTlBjOjV7NES1OlY>
OS17 NUjWXnhxSXCxcITvd4l{KEG|c3H5 MX6x5qCK|ryP NGPOc4w1QCCq NIe4[4hFVVOR NHy4V4pqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> MlLxNlU6PDR3Nk[=
MOLM13 M{fYOmFxd3C2b4Ppd{BCe3OjeR?= NX3LeJBsOjVyIH7N MlXYOFghcA>? NWTJUYxtTE2VTx?= MkTJbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk NWP5[lBWOjVyNUO4NlU>
MV4-11  NUf1eVZ5SXCxcITvd4l{KEG|c3H5 MlTQNlUxKG6P M4ruO|Q5KGh? NWqzdpdDTE2VTx?= M3rhRolv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= MUWyOVA2Ozh{NR?=
MOLM13 NFvPd2RHfW6ldHnvckBCe3OjeR?= NHLDeVAzPTBibl2= M{XMT|I1KGh? MmHRSG1UVw>? M1fEb4VvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= M1;jfFI2ODV|OEK1
MV4-11  NH\VUoJHfW6ldHnvckBCe3OjeR?= MUCyOVAhdk1? NXXXS3dOOjRiaB?= NFzGcm5FVVOR MWflcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MmL2NlUxPTN6MkW=
MOLM13 NEL6WlBCeG:ydH;zbZMhSXO|YYm= M3fSOFI2OCCwTR?= NIO5TIY1QCCq NYf3co9TTE2VTx?= M1\rfYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? MUWyOVA2Ozh{NR?=
MV4-11  NXvaVpBbSXCxcITvd4l{KEG|c3H5 MlLsNlUxKG6P MVS0PEBp MU\EUXNQ MXvpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj MVKyOVA2Ozh{NR?=
Hela NVnqcZRoS2WubDDWbYFjcWyrdImgRZN{[Xl? MYqwMVUxOCCwTR?= NUjGWYdNPzJiaB?= MVfEUXNQ M4PLfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVK0TXQ4OjVyMEmyPVU>
HBL-1 M1q0d2NmdGxiVnnhZoltcXS7IFHzd4F6 NF\QSWsxNTVyMDDuUS=> MmnZO|IhcA>? NX\zXYZQTE2VTx?= M1TKPIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1PER|I2ODB7Mkm1
HLY-1 MorMR4VtdCCYaXHibYxqfHliQYPzZZk> MYCwMVUxOCCwTR?= NEHqeWE4OiCq MVzEUXNQ MkLm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHvheYUzPTByOUK5OS=>
OCI-Ly3 NFr1O3NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NED0c5oxNTVyMDDuUS=> M3G0bFczKGh? M4TVZWROW09? NWXKR2h1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M17DVVI2ODB7Mkm1
OCI-Ly10 NIPKcGJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mk[zNE02ODBibl2= MUe3NkBp NHHmW5VFVVOR NVqzSVlP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3LkUFI2ODB7Mkm1
SU-DHL-4 MkSxR4VtdCCYaXHibYxqfHliQYPzZZk> NWmybGVkOC13MECgcm0> NWrO[5VrPzJiaB?= M1jwSmROW09? MYfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYe5XWJxOjVyMEmyPVU>
SU-DHL-5 NY\wVG9TS2WubDDWbYFjcWyrdImgRZN{[Xl? NUnVUJZoOC13MECgcm0> NXuzWnluPzJiaB?= NGjaOYlFVVOR M4DHWYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoT2NlUxODl{OUW=
SU-DHL-6 M3jUPGNmdGxiVnnhZoltcXS7IFHzd4F6 M4niZ|AuPTByIH7N NYHKbHBWPzJiaB?= NUHGSW9FTE2VTx?= MYPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3PZN|I2ODB7Mkm1
SU-DHL-10 NUXSZYNMS2WubDDWbYFjcWyrdImgRZN{[Xl? MUmwMVUxOCCwTR?= NETaSZc4OiCq NIrtOHBFVVOR MXXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4nCelI2ODB7Mkm1
RC-K8 NH3nUI5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUTJ[I9oOC13MECgcm0> MW[3NkBp NG\rWHRFVVOR M1LEOYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnfVNlUxODl{OUW=
OCI-Ly8 NVTwSFRoS2WubDDWbYFjcWyrdImgRZN{[Xl? NVPOTldxOC13MECgcm0> NVTFXWllPzJiaB?= NFLGZ|hFVVOR NUnUNo84\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH\KPHozPTByOUK5OS=>
OCL-Ly18 MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYTHUFZLOC13MECgcm0> NF\hVVY4OiCq NWjzdFJJTE2VTx?= NUO5PJk2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1zTbFI2ODB7Mkm1
OCI-Ly3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\yOFE4Oi9{NUCvOVAxKG6P NYPhbIUxOi95IHS= Mn7PSG1UVw>? NFXpSGlqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MWCyOVAxQTJ7NR?=
OCI-Ly8 M4f3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexO|IwOjVyL{WwNEBvVQ>? NXW2dmI2Oi95IHS= MkHkSG1UVw>? NF7C[plqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg M1L5NVI2ODB7Mkm1
SU-DHL-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXCOGYyPzJxMkWwM|UxOCCwTR?= NFuyUnEzNzdiZB?= MmDKSG1UVw>? MlLwbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= MWSyOVAxQTJ7NR?=
SU-DHL-10 NX;zUYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu0ZlBSOTd{L{K1NE82ODBibl2= NYTHRYdKOi95IHS= NEPiT2NFVVOR MXfpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NHzrNpYzPTByOUK5OS=>
OCI-Ly3 MVzBdI9xfG:|aYOgRZN{[Xl? MXSxO|IwOjVyIH7N Mnr1O4Q> MWTEUXNQ MYHpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NUDhWZlDOjVyMEmyPVU>
OCI-Ly8 NVzrNoo6SXCxcITvd4l{KEG|c3H5 M4PkT|E4Oi9{NUCgcm0> MVy3[C=> NXK4cpJtTE2VTx?= NHizdFdqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MUCyOVAxQTJ7NR?=
SU-DHL-4 M3\Gd2Fxd3C2b4Ppd{BCe3OjeR?= M3ezS|E4Oi9{NUCgcm0> NEXwdGI4\A>? MofXSG1UVw>? MV7pcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NGX0OWUzPTByOUK5OS=>
SU-DHL-10 NIjidGpCeG:ydH;zbZMhSXO|YYm= MVOxO|IwOjVyIH7N MoD1O4Q> MVzEUXNQ NVnRc4dVcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NIC4[JIzPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID